Safety, Efficacy and Pharmacokinetic Between Capecitabine and Exisulind in Metastatic Breast Cancer Patients

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 31, 2001

Primary Completion Date

February 28, 2003

Study Completion Date

February 28, 2003

Conditions

Breast NeoplasmsMetastases, Neoplasm

Interventions

DRUG

Capecitabine

1000 mg/m\^2 taken by mouth twice daily.

DRUG

Exisulind

125 mg taken by mouth twice daily.

Trial Locations (1)

University of Texas M. D. Anderson Cancer Center, Houston